Shares of InspireMD, Inc. (NASDAQ:NSPR) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a 1 year consensus target price of $15.00 for the company and are predicting that the company will post ($2.50) EPS for the current quarter, according to Zacks. Zacks has also assigned InspireMD an industry rank of 101 out of 255 based on the ratings given to related companies.
Separately, HC Wainwright reissued a “buy” rating on shares of InspireMD in a report on Wednesday, March 13th.
InspireMD (NASDAQ:NSPR) last posted its earnings results on Tuesday, February 19th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.82 million during the quarter.
InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.
Featured Story: What is Compound Annual Growth Rate (CAGR)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.